Hardman Research: Kelo-cote international sales

RNS Number : 7998T

Alliance Pharma PLC

17 October 2017

 

Hardman Research: Kelo-cote building international sales

Kelo-cote building international sales - Alliance Pharma's buy-and-build strategy to evolve into a profitable, cash generative, specialty pharma business is bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma has transformed the company into an internationally brand-oriented business. Performance of the enlarged group is being driven by two international growth brands, Kelo-cote and MacuShield, which are exceeding expectations, supported by bedrock products. Although the MHRA did not approve Diclectin, discussions continue which may or may not lead to reconsideration. Meanwhile, this will not impact the near-term financial performance.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/alliance-pharma-documents/17.10.17-kelo-cote-building-international-sales.pdf

To contact us:    Hardman & Co 35 New Broad Street London EC2M 1NH

Contacts: Dr Martin Hall [e-mail]  Dr Dorothea Hill [e-mail] Dr Gregoire Pave [e-mail] Telephone: [phone] Follow us on Twitter @HardmanandCo

www.hardmanandco.com  

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 

END

 

 

NRAGIBDGBBBBGRR